Cargando…

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience

Detalles Bibliográficos
Autores principales:	Yuan, Yuan, Yost, Susan E., Yim, John, Yuan, Yate-Ching, Solomon, Nicola M., Mambetsariev, Isa, Pal, Sumanta, Frankel, Paul, Salgia, Ravi, Neuhausen, Susan L., Mortimer, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617552/ https://www.ncbi.nlm.nih.gov/pubmed/28977992 http://dx.doi.org/10.18632/oncotarget.20632

Ejemplares similares

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer
por: Hill, Addie, et al.
Publicado: (2019)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity
por: Ding, Yuan Chun, et al.
Publicado: (2019)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
por: Pal, Sumanta K, et al.
Publicado: (2012)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients
por: Chan, Hei Jason, et al.
Publicado: (2015)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer
por: Hewelt, Blake, et al.
Publicado: (2019)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2022)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
por: Zarinshenas, Reza, et al.
Publicado: (2023)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Value-based genomics
por: Gong, Jun, et al.
Publicado: (2018)

Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic
por: Salgia, Sabrina, et al.
Publicado: (2021)

Gene Expression Differences in Prostate Cancers between Young and Old Men
por: Ding, Yuanchun, et al.
Publicado: (2016)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma
por: Gupta, Rohan, et al.
Publicado: (2019)

Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
por: Salgia, Ravi, et al.
Publicado: (2020)

Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors
por: Guo, Linlin, et al.
Publicado: (2023)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_74povbc48pivp236u09h3rgaph